Supplementary Table S1. Univariate logistic regression analysis of composite outcomes of COVID-19.

	Odds ratios (95% confidence interval)	P
Age	1.01 (0.94–1.07)	0.855
Sex (men)	1.64 (0.41–6.56)	0.487
Current smoker	-	-
Heart rate	1.01 (0.95–1.07)	0.829
Respiratory rate	1.04 (0.79–1.37)	0.765
Systolic BP	1.07 (1.01–1.14)	0.047
Diastolic BP	1.03 (0.99–1.07)	0.113
Symptoms on admission		
Fever	1.33 (0.33–5.39)	0.687
Cough	4.00 (0.86–18.6)	0.078
Chest tightness	1.63 (0.41–6.39)	0.487
Fatigue	2.04 (0.51–8.23)	0.316
Gastrointestinal symptoms	-	-
Comorbidities on admission		
Hypertension	1.00 (0.26–3.92)	1.000
Dyslipidemia	0.62 (0.10–3.91)	0.607
Coronary heart disease	1.41 (1.04–4.34)	0.455
Stroke	-	-
COPD	-	-

CKD	0.64 (0.05–7.83)	0.729
Hepatic diseases	-	-
Laboratory measurements		
Fasting glucose level	1.07 (0.86–1.33)	0.561
Hemoglobin A$_{1c}$	1.24 (0.76–2.01)	0.391
Alanine transaminase	1.00 (0.96–1.04)	0.848
Aspartate Aminotransferase	0.99 (0.92–1.06)	0.711
Triglyceride	0.87 (0.58–1.31)	0.500
LDL cholesterol	1.46 (0.65–3.27)	0.355
HDL cholesterol	0.72 (0.02–21.0)	0.846
eGFR	1.00 (0.99–1.01)	0.764
Uric acid	0.99 (0.99–1.00)	0.125
CRP	0.91 (0.73–1.14)	0.407
BNP	1.05 (1.02–1.08)	0.004
IL-6	1.90 (1.27–2.16)	0.007
Mean sensor glucose	1.71 (0.84–2.49)	0.218
Glucose-lowering medications	3.50 (0.35–35.1)	0.287
BP-lowering medications	1.24 (0.31–4.93)	0.762
Lipid-lowering medications	-	-
Use of glucocorticoid	0.29 (0.03–2.87)	0.287

BNP, brain natriuretic peptide; BP, blood pressure; CKD, chronic kidney disease; COPD, chronic

obstructive pulmonary disease; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL, high

density lipoprotein; IL-6, interleukin-6; LDL, low density lipoprotein.

Supplementary Table S2. Logistic regression analysis of a prolonged hospitalization (over 30 days) with different metrics derived from CGM.

	Model 1	Model 2
Sensor glucose levels, mg/dL		
TAR		
>140	1.01 (0.98–1.04)	1.00 (0.95–1.04)
>150	1.02 (0.99–1.05)	1.01 (0.95–1.06)
>160	1.03 (1.01–1.06)	1.02 (1.01–1.04)
>170	1.04 (1.01–1.07)	1.03 (1.01–1.05)
>180	1.04 (1.01–1.08)	1.04 (1.02–1.06)
>190	1.05 (1.01–1.09)	1.04 (1.02–1.07)
>200	1.05 (1.01–1.10)	1.05 (1.02–1.09)
TBR		
<70	1.17 (1.04–1.31)	1.10 (1.02–1.19)

TBR: Time below range, TAR: Time above rang; isCGM, intermittently scanned continuous glucose monitoring.

Model 1 adjusted for age and sex

Model 2 adjusted for age, sex, body mass index, symptoms on admission, systolic blood pressure, brain natriuretic peptide, IL-6 and use of glucocorticoid.

Supplementary Figure S1. The odds ratios of mean glucose levels for composite outcomes among patients with COVID-19. Adjustments were made for age, sex, body mass index, symptoms on admission, systolic blood pressure, brain natriuretic peptide, interleukin-6, and the use of glucocorticoid. Shadows represent 95% confidence intervals.